Manuscript Title Manuscript Title Manuscript Title Manuscript Title Manuscript Title Manuscript Title Manuscript Title Manuscript Title

Abstract

The abstract should be confined in a single paragraph and should not exceed 250 words. There should be no tables, figures or bibliography. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**Keywords**

Keyword 1, keyword 2, keyword 3, keyword 4, keyword 5. [Keywords should be written in alphabetical order]

1. INTRODUCTION [Times New Roman 12 bold]

Description of the work background and its aim(s) should be given in this section. The purpose(s) and hypothesis of the studyshould be indicated in the last paragraph of Introduction. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. All journal articles should cited as given in reference section [1-3].

Text body. Text body. Text body. Text body. Text body. All books should cited as given in reference section [4]. All book chapters should cited as given in reference section [5, 6]. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

Text body. Text body. Text body. Text body. Text body. All patents should cited as given in reference section [7, 8]. Text body. Text body. Text body. Text body.

All theses should cited as given in reference section [9, 10]. All conference proceedings should cited as given in reference section [11]. Text body. Text body. All websites should cited as given in reference section [12].

Osmaniye et al. [1] reported that. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Rouzer and Marnett [2] reported that.

The purpose(s) and hypothesis of the study should be stated in the last paragraph of Introduction. Text body. Text body. Text body. Text body. Text body. Text body. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.Text body. Text body. Text body. Text body.

2. MATERIALS AND METHODS [1st level]

This section should be brief, clear, and without unnecessary details. Studies based on animal experiments should include an approval statement of Ethical Committee in this section. Type of research (descriptive, observation, experimental), characteristics of study subjects, inclusion and exclusion criteria, the sampling method if used in conjunction with the data collection phase, and reason for sampling method without probability if used should be indicated. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

2.1. Chemistry [2nd level]

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**2.2. Heading Title [2nd level]**

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**2.2.1. Heading title [3rd level]**

Please use only three levels. Text body. Text body. Text body. Text body. P value should be written uppercase letter.

**2.3. Heading Title [2nd level]**

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**2.3.1. Statistical analysis [3rd level]**

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**3. RESULTS AND DISCUSSION**

In this section, a clear presentation of experimental results should be given (Table 1). The stated data in tables or figures should not be repeated in the text. The findings should be discussed using current literature.

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body (P<0.05).

**3.1. Heading Title [2nd level]**

Results and Discussion section can be written separately depending on the preference of the authors. When Results and Discussion are written separately, each section should be numbered separately. Text body. Text body. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body (Figure 1).

**3.2. Heading Title [2nd level]**

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**3.3. Heading Title [2nd level]**

Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

**4. CONCLUSION**

The conclusions of the study should be stated in this paragraph. Text body. Text body. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body. Text body.

REFERENCES

1. Osmaniye D, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Synthesis and characterization of new piperazine-dithiocarbamate compounds as potent MAO-A inhibitors. Eur J Life Sci. (2022); 1(1):1-7. https://doi.org/10.55971/EJLS.1089254
2. Rouzer CA, Marnett LJ. Structural and chemical biology of the interaction of cyclooxygenase with substrates and non-steroidal anti-inflammatory drugs. Chem Rev. (2020);120(15):7592-7641. https://dx.doi.org/10.1021/acs.chemrev.0c00215
3. Krammer, F. SARS-CoV-2 vaccines in development. Nature. (2020);586:516–527. https://doi.org/10.1038/s41586-020-2798-3
4. Wilson CG, Crowley PJ. Controlled release in oral drug delivery. New York: Springer; (2011). ISBN:978-1-4614-1003-4
5. Ağalar HG. Chapter 7 - *Vaccinium macrocarpon* Ait. and urinary tract infections. In: Atta-ur-Rahman, editor. Studies in Natural Products Chemistry. Amsterdam: Elsevier; (2022). p. 267-288. ISBN:978-0-323-91250-1
6. Verma R, Raj S, Berry U, Ranjith-Kumar CT, Surjit M. Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges. In: Sobti RC, Lal SK, Goyal RK, editors. Drug Repurposing for Emerging Infectious Diseases and Cancer. Singapore: Springer; (2023). p. 451–478. ISBN: 978-981-19-5398-9
7. Wong HL, Narvekar M, Xue HY, inventors; Temple University, assignee. Nanospheres for therapeutic agent delivery. United States patent no 9724304. (2017).
8. Yılmaz N, Altıntop MD, Akalın Çiftçi G, Sever B, inventors; Anadolu University, assignee. New triazole and triazolothiadiazine derivatives exerting cytotoxic and apoptotic effects on A549 cells through Akt inhibition. Turkish patent no 2020/10296. (2022).
9. Arora HC. Doxorubicin-Nanocarriers Enhance Doxorubicin Uptake and Clathrin-Mediated Endocytosis in Drug-Resistant Ovarian Cancer Cells [Ph.D.]. Illinois: Northwestern University; (2012).
10. Finn NA. Role of redox systems in doxorubicin metabolism and doxorubicin-mediated cell signaling: a computational analysis [Ph.D.]. Atlanta: Georgia Institute of Technology; (2011).
11. Altıntop MD, Temel HE, Özdemir A. A series of imidazole derivatives as new anticholinesterase agents. 13th International Conference on Alzheimer's and Parkinson's Diseases (ADPD 2017); March 29-April 2, 2017; Vienna-Austria.
12. World Health Organization (2023, February 11). Cholera – Global situation. Retrieved April 4, 2023, from https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON437

**Table 1.** Table title

|  |  |
| --- | --- |
|  | **Heading** |
| **Heading** | **Heading** | **Heading** | **Heading** | **Heading** |
| Row heading (units) |  |  |  |  |
| Row heading (units) | 0.10a | Valuea,b | Valueb | Valuec |
| Row heading (units) | 0.20 | Value | Value | Value |
| Row heading (units) | 0.25 | Value | Value | Value |

a,b,c Values within a row with different superscripts differ significantly at P<0.0.

Place figure here

Figure 1. Figure title

**IMPORTANT NOTES**

* Figures and tables should not be submitted in separate files.
* In case the manuscript is accepted, the authors may be asked to provide source files of figures, if deemed necessary.
* All figures should be cited in the manuscript in a consecutive order. Figures should be supplied in either vector art formats (Illustrator, EPS, WMF, FreeHand, CorelDraw, PowerPoint, Excel, etc.) or bitmap formats (Photoshop, TIFF, GIF, JPEG, etc.).
* Bitmap images should be of 300 dpi resolution at least unless the resolution is intentionally set to a lower level for scientific reasons.